Insider · CIK 0001291937
William C Bertrand JR
Files at ARDX (ARDELYX, INC.), ADAPY (Adaptimmune Therapeutics PLC). First filing Jan 12, 2024, latest Aug 29, 2025.
In brief
William C Bertrand JR files SEC Form 4 as COO and director at ADAPY (Adaptimmune Therapeutics PLC), and also at ARDX (ARDELYX, INC.). Since Jan 12, 2024, William C Bertrand JR has reported 0 open-market buys worth $0 and 5 open-market sells worth $41k, the latest filed on Aug 29, 2025.
A track record needs three past buys with six months of prices behind them; William C Bertrand JR has 0, so none is measured yet.
The newest scored trade: sold $2,091 of ADAPY on Aug 28, 2025, filed Aug 29, 2025, scored 40 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ADAPY: Adaptimmune Therapeutics PLC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Adaptimmune Therapeutics PLC | $2,091 207,000 shares | -17% | - | |
| 45Moderate | Adaptimmune Therapeutics PLC | $3,243 5,584 shares | -43% | - | |
| 55Moderate | Adaptimmune Therapeutics PLC | $11k 19,542 shares | -193% | - | |
| 55Moderate | Adaptimmune Therapeutics PLC | $16k 23,589 shares | -202% | +66% from low-62% from high | |
| 55Moderate | Adaptimmune Therapeutics PLC | $7,813 9,229 shares | -91% | +105% from low-53% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 29, 2025 | ADAPY Adaptimmune Therapeutics PLC | 34,500 0.01% of outstanding | $2,070 | Aug 28, 2025 | none |
| Jan 17, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5,584 0.00% of outstanding | $3,243 | Jan 17, 2025 | $11k |
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | 9,739 0.00% of outstanding | $5,726 | Jan 13, 2025 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +12,345 | $0.00 | $0 | 303,052 | Jun 18, 2026 |
| Jun 16, 2026 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +26,455 | $0.00 | $0 | 329,507 | Jun 18, 2026 |
| Jun 16, 2026 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +39,715 | $0.00 | $0 | 39,715 | Jun 18, 2026 |
| Aug 28, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale Ordinary Shares with a nominal value of GBP0.001 per share | -207,000 | $0.01 | $2,091 | 986,352 | Aug 29, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +19,390 | $0.00 | $0 | 249,156 | Jun 23, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +41,551 | $0.00 | $0 | 290,707 | Jun 23, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +54,059 | $0.00 | $0 | 54,059 | Jun 23, 2025 |
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,612,032 | $0.00 | $0 | 1,612,032 | Feb 20, 2025 |
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,074,696 | $0.00 | $0 | 1,074,696 | Feb 20, 2025 |
| Jan 17, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,584 | $0.58 | $3,243 | 7,510 | Jan 17, 2025 |
| Jan 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -4,268 | $0.59 | $2,509 | 5,845 | Jan 15, 2025 |
| Jan 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,471 | $0.59 | $3,216 | 7,623 | Jan 15, 2025 |
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -9,803 | $0.57 | $5,635 | 13,756 | Jan 15, 2025 |
| Jan 16, 2024 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -4,681 | $0.79 | $3,698 | 7,023 | Jan 17, 2024 |
| Jan 15, 2024 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +2,544,432 | $0.00 | $0 | 2,544,432 | Jan 17, 2024 |
| Jan 17, 2024 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,309 | $0.67 | $3,573 | 7,785 | Jan 17, 2024 |
| Jan 15, 2024 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +565,416 | $0.00 | $0 | 565,416 | Jan 17, 2024 |
| Jan 17, 2024 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -13,599 | $0.67 | $9,152 | 20,201 | Jan 17, 2024 |
| Jan 11, 2024 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -4,009 | $0.84 | $3,354 | 6,104 | Jan 12, 2024 |
| Jan 12, 2024 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,220 | $0.85 | $4,458 | 7,874 | Jan 12, 2024 |
Questions about William C Bertrand JR
Answered from the filings on this page, as of the latest one.
Is William C Bertrand JR buying or selling?
Not in the last 12 months. William C Bertrand JR's latest open-market trade on SEC Form 4 was sold $2,091 of ADAPY on Aug 28, 2025.
How did William C Bertrand JR's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and William C Bertrand JR has 0.
Where does William C Bertrand JR file Form 4?
William C Bertrand JR has filed Form 4 at ADAPY (Adaptimmune Therapeutics PLC) as Chief Operating Officer; ARDX (ARDELYX, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.